Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Evofem Biosciences (EVFM) Misses Q1 EPS by 8c
May 6, 2020 8:05 AM EDTEvofem Biosciences (NASDAQ: EVFM) reported Q1 EPS of ($0.40), $0.08 worse than the analyst estimate of ($0.32).
"We are now less than three weeks away from the PDUFA date for Phexxi and the potential to deliver the first non-hormonal contraceptive innovation in decades. We are... More
